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ABSTRACT
Management of castration-resistant prostate cancer (CRPC) is challenging
due to lack of efficacious therapy. Luteinizing hormone-releasing hormone (LHRH)
analogs appear to act directly on cells based on the LHRH receptors on human
prostate adenocarcinoma cells. We explored anticancer activity of a cytotoxic analog
of LHRH, AEZS-108, consisting of LHRH agonist linked to doxorubicin. Nude mice
bearing DU-145 tumors were used to compare antitumor effects of AEZS-108 with
its individual constituents or their unconjugated combination. The tumor growth
inhibition of conjugate was greatest among treatment groups (90.5% inhibition vs.
41% by [D-Lys(6)]LHRH+DOX). The presence of LHRH receptors on DU-145 cells
was confirmed by immunocytochemistry. In vitro, AEZS-108 significantly inhibited
cell proliferation (61.2% inhibition) and elevated apoptosis rates (by 46%). By the
detection of the inherent doxorubicin fluorescence, unconjugated doxorubicin was
seen in the nucleus; the conjugate was perinuclear and at cell membrane. Autophagy,
visualized by GFP-tagged p62 reporter, was increased by AEZS-108 (7.9-fold vs. 5.3fold by DOX+[D-Lys(6)]LHRH. AEZS-108 more effectively increased reactive oxygen
species (ROS, 2-fold vs. 1.4-fold by DOX+[D-Lys(6)]LHRH) and levels of the apoptotic
regulator p21 in vivo and in vitro. We demonstrate robust inhibitory effects of the
targeted cytotoxic LHRH analog, AEZS-108, on LHRHR positive castration-resistant
prostate cancer cells.

INTRODUCTION

therapy (ADT) currently achieved by surgical orchiectomy
or by treatment with LHRH agonist or antagonist
[2-4]. Continuous administration of LHRH analogs
downregulates pituitary LHRH receptors thus leading to
the suppression of gonadotropin (luteinizing hormone and
follicle-stimulating hormone) release and a consequent

In 2014, prostate cancer is expected to account
for 27% of newly detected cancers and 10% of cancerrelated deaths in men in the US [1]. Standard therapy
of metastatic prostate cancer is androgen deprivation
www.impactjournals.com/oncotarget
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drop in production of gonadal androgens [2, 5]. However,
the attenuation of this pituitary-gonadal axis is preceded
by an initial surge of LH that, in some cases, is responsible
for a serious side effect termed “flare reaction” [6, 7]. To
avoid side effects, antagonistic analogs of LHRH, that
completely lack LH-releasing activity, have also been
developed and approved for the management of advanced
androgen-dependent prostate cancer [8-10].
Despite the initial success of ADT on suppressing
tumor growth, prostate cancer cells may progress to
androgen independence (also referred to as castration
resistance) which situation narrows the number of effective
treatments. Patients with castrate resistant prostate cancer
(CRPC) have a poor prognosis with an expected survival
of less than 19 months [11]. There are a few treatment
options of chemotherapy for advanced CRPC but none of
them are markedly effective [12].
LHRH and its receptor (LHRH-R) are not limited to
the hypothalamic-pituitary axis [13]. In the periphery, the
LHRH system regulates gonadal functions and appears to
serve as a growth factor of benign conditions [14-17] and
various cancers including breast, lung, ovary, endometrial,
kidney, bladder, colon, pancreas and prostate [18-25].
A specific, medium to high-affinity binding site for an
LHRH agonist was found in 86% of prostate cancers [23].
In addition, expression of LHRH receptor by prostate
cancer cells is preserved even after a prolonged exposure
to LHRH agonist; LHRH receptors also appear in lymph
node metastases [26]. These findings imply that the LHRH
receptor is a suitable object for the design of an approach
based on targeted chemotherapy [27]. Accordingly,
various cytotoxic conjugates of LHRH have been
produced of which AEZS-108 (previously known as AN152) has been chosen for clinical development [28-30].
This compound consists of an agonistic analog of LHRH,
[D-Lys6]-LHRH, linked to the cytotoxic anthracycline,
doxorubicin. In this hybrid, doxorubicin remains active
and becomes specifically targeted to cells that possess
cell membrane LHRH receptors, thereby making it less
toxic to other cells [31, 32]. The unconjugated doxorubicin
diffuses through the cell membranes and accumulates
in the nucleus where it intercalates into the DNA. By
targeting topoisomerase-II, it triggers enzyme-mediated
DNA damage [33, 34]. Furthermore, doxorubicin elevates
the concentration of reactive oxygen species (ROS) and
triggers the activation of the ceramide signaling pathway –
both processes being antiproliferative and toxic to the cells
[35-40]. In contrast, AEZS-108 is taken up by the cells
by receptor internalization and the doxorubicin moiety is
subsequently cleaved off in the cell [41, 42]. This suggests
a delayed doxorubicin-induced cytotoxicity in cells that
are otherwise sensitive to doxorubicin. However, previous
findings showed that AEZS-108 is more effective in
inducing apoptosis in ovarian and endometrial carcinoma
cell lines in vitro than doxorubicin alone [43].
In the current study, we investigated the antitumor
www.impactjournals.com/oncotarget

activity of AEZS-108 in the CRPC DU-145 tumors in vivo
and in vitro. Additionally, we explored the mechanism of
its action in vitro, by studying its intracellular dynamics,
measuring its effect on apoptosis and autophagy, and
detecting its potential to activate doxorubicin-mediated
intra- and extranuclear signals. Our findings indicate
that AEZS-108 is a highly promising compound for the
treatment of CRPC not only due to its targeted nature
but also because of the potential of the different uptake
mechanism to strengthen the extranuclear toxic activity
of doxorubicin.

RESULTS
Inhibition of tumor growth in nude mice by
AEZS-108
Nude mice bearing xenografted tumors of castrationresistant prostate DU-145 cells were randomized into 5
treatment groups: control (vehicle), AEZS-108 (6.9 µmol/
kg), DOX (6.9 µmol/kg), [D-Lys(6)]LHRH (6.9 µmol/
kg), and the combination of unconjugated DOX and
[D-Lys(6)]LHRH (Fig.1A). Tumor growth was already
significantly decreased compared to control at week
1 (71% inhibition vs control, p<0.01); this remained
significant throughout the 8 weeks of treatment. The
cytotoxic LHRH analog completely blocked tumor
growth at the end of the treatment resulting in a 90.5 %
inhibition compared to control and was also significantly
better than [D-Lys(6)]LHRH (p<0.01) and DOX alone
(p<0.05). The unconjugated DOX, [D-Lys(6)]LHRH
or their combination were unsuccessful in inducing
significant reduction in tumor growth. As revealed by
Western blot analysis of tumors removed at the end of the
treatment, AEZS-108 was also highly potent in elevating
protein levels of p21, a key activator of tumor suppressor
pathways (Fig.1B).

Immunocytochemical localization of LHRH
receptors in DU-145 cells
Expression and cellular distribution of LHRH
receptors in castration-resistant DU-145 cells was revealed
by immunocytochemistry (Fig.2). We found that LHRH
receptors are present on the cell membrane and therefore
they can act to facilitate the selective uptake of AEZS-108
in these cells.

AEZS-108 inhibits proliferation and increases
apoptotic cell death in DU-145 cells
Cell density was measured after a two-day
incubation with 100 nM or 250 nM doxorubicin (DOX),
4568
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[D-Lys(6)]LHRH) (LHRH), the combination of DOX
and LHRH or AEZS-108, respectively, by the MTS
assay. DOX and its combination with LHRH reduced
the proliferation by 14.8% (p<0.01) and 11.3% (p<0.05)
at 100 nM concentration, respectively, and 52% and
42.8% at 250 nM concentration (p<0.001), respectively,
compared to control. LHRH on its own had little effect

on proliferation. The cytotoxic compound, AEZS-108
on the other hand was the most efficacious in inhibiting
proliferation, reducing it by 23.2 % and 61.2 % at 100
nM and 250 nM (p<0.001), respectively, compared to
control. The increase in apoptotic cell death was measured
after a 1-day incubation with 1 µM DOX, [D-Lys(6)]
LHRH), their combination or AEZS-108, respectively, by
measuring the binding of FITC-conjugated Annexin-V.
The elevation in apoptotic cell death was only significant
when AEZS-108 was used (46% elevation, p<0.05).

Figure 1: Treatment with cytotoxic luteinizing
hormone-releasing hormone (LHRH) analog, AEZS108, significantly inhibited the growth of DU-145
castration-resistant prostate cancer xenografted into
nude mice and upregulated the protein levels of p21
WAF1/Cip1. A: Mice were given vehicle (control), 6.9 µmol/

kg AEZS-108, 6.9 µmol/kg doxorubicin (DOX), 6.9 µmol/kg
[D-Lys(6)]LHRH) or the combination of unconjugated DOX
and [D-Lys(6)]LHRH in weekly i.v. injections. Tumor volumes
were assessed each week and percent changes in tumor volumes
are shown (± SEM) relative to tumor volumes at the initiation
of treatment. Statistical analysis was performed by one-way
ANOVA, followed by Holm-Sidak test.*: p < 0.05, **: p < 0.01,
***: p < 0.001 vs. control. B: Western blot showing protein
levels of p21 WAF1/Cip1 in tumors collected at the end of the
experiment. β-actin was used as loading control. Fold-changes
in protein levels are shown relative to control and normalized
to β-actin levels. Membrane shown is representative of two
experiments.

Figure 2: DU-145 cells express receptors of LHRH
on the cell membrane. LHRH receptors were labelled by

using immunocytochemistry (green), the actin cytoskeleton was
visualized by TRITC-conjugated phalloidin (red) and nuclei
were stained with DAPI (blue). Scale bar corresponds to 100
µm.

Figure 3: AEZS-108 suppresses the proliferation (A) and induces apoptosis (B) in DU-145 castration-resistant prostate
cancer cells in vitro. A: Cells were split into a 96-well plate at 5000 cells/well density, starved for one day in serum free medium and
treated with 100 nM or 250 nM of doxorubicin (DOX), [D-Lys(6)]LHRH (LHRH), the combination of DOX and LHRH or AEZS-108 in
0.5 % serum-containing growth medium. B: The density of apoptotic cells were measured by detecting the accumulation of annexin-V after
a 1-day treatment with 1 µM doxorubicin (DOX), [D-Lys(6)]LHRH (LHRH), the combination of DOX and LHRH or AEZS-108 diluted in
serum-free medium. Statistical analysis was performed by one-way ANOVA, followed by Holm-Sidak test.*: p < 0.05, **: p < 0.01, ***:
p < 0.001 vs. control.
www.impactjournals.com/oncotarget
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The intracellular distribution of AEZS-108 and
the unconjugated doxorubicin are dissimilar

The cytotoxic LHRH analog, AEZS-108, increases
the rate of autophagy and the generation of
reactive oxygen species (ROS)

The intrinsic fluorescence of doxorubicin was
detected in DU-145 cells after they were treated with
either 5 µM unconjugated doxorubicin or AEZS-108
(Fig.4.). After 20 or 60 minutes of incubation, the
unconjugated doxorubicin was predominantly localized in
the nucleus. In contrast, the cytotoxic LHRH compound
showed a gradual cellular uptake, accumulating at the
cell membrane and in the perinuclear space and showing
a limited presence in the nucleus. This indicates that the
compound spends extended time outside the nucleus
before the subsequently cleaved doxorubicin reaches the
nuclear DNA.

The induction of autophagy was measured after 1
day of incubation with 1µM DOX, [D-Lys(6)]LHRH,
the combination of DOX and LHRH or AEZS-108,
respectively, by using the GFP-tagged p62 reporter
construct (Fig.6a). Doxorubicin, [D-Lys(6)]LHRH and
their unconjugated combination increased the rate of
autophagy by 5, 3.5 and 5.3-fold, respectively, although
the effect of [D-Lys(6)]LHRH alone was not significant
(p<0.01 for DOX and DOX + [D-Lys(6)]LHRH. More
intriguingly, AEZS-108 increased the rate of autophagy by
8-fold (p<0.001). The effect of the same treatments on the
generation of ROS was measured by a 3′-(p-aminophenyl)
fluorescein. Only the cytotoxic compound AEZS-108
increased the level of ROS significantly (2-fold increase,
p<0.01).

Short-term treatment with AEZS-108 and
doxorubicin
To assess the difference in DNA damage caused by
a short term incubation with the unconjugated doxorubicin
or AEZS-108, we used immunocytochemistry with an
antibody recognizing the phosphorylated form of the
histone variant, γ-H2AX (Fig.5). After 60 minutes of
incubation, the unconjugated form of doxorubicin was
noticeably more efficient than AEZS-108 in increasing
the phosphorylation of γ-H2AX. This finding provides
evidence for the delayed transport of doxorubicin when it
is in conjugated form in the cytotoxic compound, AEZS108.

AEZS-108 and doxorubicin regulate the protein
level of p21 and the phosphorylation of γ-H2AX
differently
Protein levels of p21 and the phosphorylation
of γ-H2AX were measured after 1 day of incubation
with 1µM DOX, [D-Lys(6)]LHRH, their unconjugated
combination or AEZS-108, respectively, in DU-145 cells.
Interestingly, p21 level was elevated by AEZS-108 to a
much higher extent than was achieved by the incubation
with the unconjugated DOX and [D-Lys(6)]LHRH
combination. In contrast, the phosphorylation of γ-H2AX
was similar in the DOX, DOX+[D-Lys(6)]LHRH and

Figure 4: The intracellular distribution of AEZS-108 and doxorubicin are different after a short incubation in DU-145
castration-resistant cells. Cells were incubated with 5 µM unconjugated doxorubicin or AEZS-108 for 20 or 60 minutes in serum-free
medium. Nuclei were labelled with Hoechst dye (blue). Cells were fixed in 4% paraformaldehyde, mounted and images were acquired
immediately by using the inherent fluorescence of doxorubicin. Scale bar corresponds to 10 µm.
www.impactjournals.com/oncotarget
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AEZS-108 treated cells, indicating that the doxorubicin
moiety subsequently cleaved from AEZS-108 also reached
and caused damage in the nucleus. Histone H3 and β-actin
were used as loading controls.

prostate cancer as well as in glioblastoma [13, 28-30, 5153]. More than 80% of resected human prostate cancers
express LHRH receptors suggesting that patients with
prostatic malignancies would benefit from therapy with
the cytotoxic LHRH analog, AEZS-108 [23].
In an earlier study, AEZS-108 suppressed the
growth of the human androgen sensitive MDA-PCa-2b

DISCUSSION
Cytotoxic conjugates of peptide analogs assist
the tumor-specific targeting of cytotoxic drugs thereby
increasing efficacy and limiting toxicity to the nontumoral tissue [27, 44-50]. LHRH was selected for the
development cytotoxic conjugates based on the presence
of its receptor in various tumoral tissues including
ovarian, endometrial, colorectal, pancreatic, bladder and
Figure 5: The phosphorylation of the DNA
breakdown marker, γ-H2AX, is markedly stimulated
by doxorubicin but less affected by AEZS-108 in
short-term experiments. Cells were incubated with 5 µM
unconjugated doxorubicin or AEZS-108 for 60 minutes in serumfree medium. Cells were then fixed in 4% paraformaldehyde
and the phosphorylated γ-H2AX was labelled by using
immunocytochemistry (green). Nuclei were labelled with DAPI
(blue). Scale bar corresponds to 100 µm.

Figure 6: The cytotoxic LHRH analog, AEZS-108, induces autophagy (A) and increases the level of intracellular ROS
(B) in the DU-145 castration-resistant prostate cancer cells. Cells were incubated with 1 µM doxorubicin (DOX), [D-Lys(6)]

LHRH) (LHRH), the combination of DOX and LHRH or AEZS-108 for 24 hours in serum-free medium. The rate of autophagy was measured
by labelling autophagosomes with the GFP-tagged p62 reporter transduced by baculovirus. ROS level was detected by APF fluorescent
reagent. Fluorescent intensity was measured with a Victor3 plate reader. After measurement, cells were fixed in 4% paraformaldehyde and
representative images were taken with a Nikon Eclipse Ti fluorescence microscope with a 20x objective. Statistical analysis was performed
by one-way ANOVA, followed by Holm-Sidak test.*: p < 0.05, **: p < 0.01, ***: p < 0.001 vs. control.

Figure 7: AEZS-108 elevates the protein level of p21
WAF1/Cip1 but its effect on the phosphorylation
of γ-H2AX is comparable to that of unconjugated
doxorubicin. Cells were incubated with 1 µM doxorubicin

(DOX), [D-Lys(6)]LHRH) (LHRH), the combination of DOX
and LHRH or AEZS-108 for 24 hours in serum-free medium
and then were lysed and were subjected to Western blot analysis.
A Histone H3 and β-actin were used as loading controls. Foldchanges in p21 protein levels are shown relative to control and
normalized to β-actin levels. Membrane shown is representative
of two experiments.
www.impactjournals.com/oncotarget
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and LNCaP cells as well as increased the rate of apoptosis
in the castration-resistant bone metastasis model of C4-2
prostate cancer cells [29]. Our aim here was to further
elucidate the antitumor effects of AEZS-108 in castrationresistant prostate cancer, a tumor that otherwise lacks
effective treatment strategies. We selected an established
cell line, DU-145, that is derived from a brain metastasis
and manifests an epithelial nature [54], to compare the
inhibitory activity of AEZS-108 with its unconjugated
constituents, doxorubicin and [D-Lys(6)]LHRH. We
found that the effect of AEZS-108 was much greater than
that of the doxorubicin alone, or its combination with the
unconjugated LHRH in completely blocking and reversing
tumor growth. This high efficacy of the cytotoxic analog
AEZS-108 is likely due to its accumulation in LHRH
receptor positive DU-145 cells, since the combination of
unconjugated DOX and [D-Lys(6)]LHRH was much less
effective in suppressing tumor growth.
In previous studies, AEZS-108 was also more
effective than equimolar doses of doxorubicin to inhibit
the growth of experimental human breast, bladder,
pancreatic, ovarian and endometrial cancers [13, 51, 53,
55, 56]. These experimental reports led to the first clinical
trials that were carried out starting in 2008 [57]. A phase-I
dose escalation study was completed in women with
LHRH receptor positive ovarian, endometrial and breast
cancer [32] and was followed by two phase II studies in
patients with taxane-pretreated platinum-resistant ovarian
cancer and with recurrent endometrial cancer [58, 59].
These studies showed no major toxicity in pituitary, heart
or other organs [58, 59]. AEZS-108 was more efficient in
patients with recurrent endometrial cancer: 5% of patients
had a complete and 18% a partial remission; moreover, in
44%, the disease was stable for at least 6 weeks [59]. A
phase I study with taxane- and castration-resistant prostate
cancer has also been finished rendering AEZS-108 safe for
its use in phase II and III trials that are currently ongoing
(unpublished).
The increased antitumoral activity of the cytotoxic
LHRH analog resides in its ability to home the doxorubicin
moiety to LHRH receptor positive cancer cells where it
undergoes binding and internalization [41, 42]. By using
immunocytochemistry, we confirmed that the DU-145
castration-resistant prostate cancer cells express LHRH
receptors that are localized on the cell membrane rendering
them susceptible to AEZS-108. In addition, we showed
that there is a slow uptake of AEZS-108 in DU-145 cells,
an effect, which may be responsible for its high efficacy in
vitro. After a short, one-hour incubation with the cytotoxic
analog, AEZS-108 was present at both the cell membrane
and in the perinuclear area whereas doxorubicin diffused
through the membrane to accumulate in the nucleus.
Similar uptake dynamics of AEZS-108 have been shown
in breast, ovarian and endometrial cancer cells by others,
however, the authors have not compared the uptake of
AEZS-108 to that of the unconjugated doxorubicin, and
www.impactjournals.com/oncotarget

the significance of this extended extranuclear residence
has not been discussed [41, 60].
Since the accumulation of doxorubicin derived
from AEZS-108 in the nucleus is delayed, it is unlikely
that the increased activity of the compound is due to
its elevated effect on topoisomerase-II activity. This is
supported by our finding that the phosphorylation of the
DNA-breakdown marker, γH2AX, is lower after a short
incubation with AEZS-108 than with the unconjugated
doxorubicin. An alternative cytotoxic mechanism for
doxorubicin is considered to be its capability to raise
the levels of ROS which process occurs mainly in the
cytoplasm and mitochondria [61-63]. Accordingly,
doxorubicin has been shown to increase the level of
hydrogen peroxide in PC3 prostate cancer cells [64]. Since
AEZS-108 remains extranuclear for an extended time, it is
expected to influence intracellular ROS levels to a greater
extent than the unconjugated DOX. Indeed, we found that
AEZS-108 elevated ROS levels more significantly than
the unconjugated DOX. In addition, higher ROS levels
may contribute to the increased apoptotic effect of AEZS108 seen in our experiment [65].
Bioactive sphingolipids such as sphingosine,
sphingosine-1-phosphate and ceramide are important
regulators of survival, cell proliferation and death
[35]. Increased levels of ceramide affect the activity of
diverse signaling molecules leading to cell cycle arrest,
autophagy and apoptosis [36]. Recently, doxorubicin has
been shown to promote the synthesis of ceramide [3739]. Accumulation of ceramide induced by doxorubicin
stimulates the proteolytic activation of CREB3L1, a
transcription factor responsible for the transcription of
various genes that inhibits cell proliferation, including
p21 [38, 40]. The extended presence of AEZS-108 on
cell membranes may facilitate the synthesis of ceramide
and it may thereby produce a greater effect on this
pathway than the unconjugated doxorubicin which simply
diffuses across membranes [33, 34]. This idea seems to
be supported by the increased rate of autophagy and the
elevated levels of p21 in response to AEZS-108 in our
experiments, both processes being regulated partly by the
ceramide pathway [36]. However, further investigation is
required to better understand the role of this pathway in
cytotoxicity induced by AEZS-108.
In conclusion, our results indicate that patients
with castration-resistant prostate cancer may benefit
from chemotherapy based on the targeted cytotoxic
LHRH analog, AEZS-108. The peptide-conjugated form
of doxorubicin allows a slower intracellular uptake of
this drug that leads to increased effects on extranuclear
targets, such as the generation of ROS and the activation
of the ceramide pathway. Our findings provide a better
understanding of the mechanism of action of cytotoxic
peptide analogs and substantiate their use in clinical
practice.
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METHODS

incubated for 24 hrs. After 24 hrs, culture medium was
replaced by serum-free medium for another 24 hrs. This
was followed by the addition of 100 nM or 250 nM of
unconjugated doxorubicin, [D-Lys(6)]LHRH), their
combination, or AEZS-108 in medium containing 0.5
% heat-inactivated serum; the cells were then incubated
for a further 48 h. At the end of the treatment the relative
number of viable cells was measured using MTS assay
(CellTiter 96 AQueous Assay; Promega, Madison, WI)
following manufacturer’s instructions. Absorbance was
measured at 490 nm in a Victor 3 Multilabel Counter
(Perkin-Elmer, Waltham, MD). Experiments were
performed in hexaplicate. Values were expressed relative
to the control.

Cytotoxic compounds
LHRH agonist [D-Lys6]LHRH (pyroGlu-His-TrpSer-Tyr-D-Lys-Arg-Pro-Gly-NH2) was synthesized in
our laboratory by solid-phase methods as described [66].
DOX.HCl salt was purchased from Chemex Export-Import
GmbH (Vienna, Austria). Cytotoxic LHRH conjugate
AN-152 was first synthesized in our laboratory [27, 28].
AEZS-108 was made by AEterna/Zentaris (Frankfurt
am Main, Germany). The compounds were dissolved in
0.01 M aqueous acetic acid and diluted with 5.5% (w/v)
aqueous D-mannitol.

Apoptosis assay

Cell culture

Cells were seeded into a 24-well plate at 100,000
cells/well density in complete growth medium and were
incubated for 24 hrs. Afterwards, medium was replaced
with serum-free medium containing 1 µM unconjugated
doxorubicin, [D-Lys(6)]LHRH), their combination,
or AEZS-108. Twenty-four hours later, cells were
trypsinized, collected into microcentrifuge tubes and the
rate of apoptosis was measured by the Multi-Parameter
Apoptosis Assay Kit (Cayman Chemical Company, Ann
Arbor, MI) according to the manufacturer`s instructions.
Experiments were performed in triplicate. Values were
expressed relative to the control.

The DU-145 castration-resistant prostate cancer
cell line was obtained from the American Type
Culture Collection (ATCC; Manassas, VA) and was
maintained in culture using Eagle`s Minimum Essential
Medium (EMEM; ATCC) supplemented with 10%
FBS and antibiotics (100 U/mL penicillin, 100 μg/mL
streptomycin). Cells were grown at 37 °C in a humidified
95% air/5% CO2 atmosphere.

Animals and in vivo xenograft models of DU-145
tumors

Detection of ROS

Male athymic nude mice (Ncr nu/nu) were
obtained from the NCI (Frederick Cancer Research and
Development Center, Frederick, MD), and maintained
under pathogen-limited conditions. Four donor animals
were injected subcutaneously with 107 DU-145 cells. The
resulting tumors were removed aseptically and minced
into 3 mm3 pieces for transplantation into both flanks of
animals that was performed using trocar needles. When
tumors reached an average volume of 65 mm3, mice
were randomized into five groups with nearly equal
average tumor sizes. Mice received weekly intravenous
injections of 6.9 µmol/kg doxorubicin, [D-Lys(6)]LHRH,
their combination, AEZS-108 or vehicle. Tumor size
was measured with a microcaliper at each week. Tumor
volume [67] and tumor inhibition [68, 69] were calculated
as previously described. At the end of the experiment,
mice were sacrificed by cervical dislocation and tumors
were removed and snap frozen. Specimens were stored at
-80oC for further investigation.

Cells were seeded at 20,000 cells/well density
into a 96-well plate in complete growth medium. One
µM unconjugated doxorubicin, [D-Lys(6)]LHRH), their
combination, or AEZS-108 was added to the cells in
serum-free medium for 24 hrs. The ROS sensor reagent,
aminophenyl fluorescein (Life technologies, Grand Island,
NY) was added to the cells at 5 µM concentration for 20
minutes. Medium was replaced with serum- and phenol
red-free medium and fluorescence was measured in a
Victor 3 Multilabel Counter (at excitation and emission
wavelengths of 485 nm and 535 nm, respectively).
Experiments were performed in hexaplicate. Values were
expressed relative to the control.

Measurement of density of autophagic vacuoles
Cells were seeded at 20,000 cells/well density
into a 96-well plate in complete growth medium. The
next day, cells were transduced by green fluorescent
protein-tagged LC3B protein by using the baculovirus
technique (Premo™ Autophagy Sensor, Life technologies)
according to the manufacturer`s instructions. Medium

Proliferation assay
Cells were seeded in 96-well plates at 2,500 cells/
well density in complete growth medium and were
www.impactjournals.com/oncotarget
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was replaced the next day with serum-free medium
containing 1 µM unconjugated doxorubicin, [D-Lys(6)]
LHRH), their combination or AEZS-108. Fluorescence
was detected in serum- and phenol red-free medium in a
Victor 3 Multilabel Counter (at excitation and emission
wavelengths of 485 nm and 535 nm, respectively).
Experiments were performed in hexaplicate. Values were
expressed relative to the control.

Immunocytochemistry
microscopy

and

separated by 4-15% PAGE and were transferred onto
PVDF membrane. Blocking was performed with Clear
milk blocking buffer (Thermo Fisher Scientific) for half
an hour. Primary antibodies p21, γ-H2AX, Histone H3
(1:1000 dilution, Cell Signalling Technology) and β-actin
(1:10,000 dilution, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) were added to the membranes for overnight
incubation. Species-specific HRP-conjugated secondary
antibodies (Thermo Fisher Scientific) were left on the
membranes for 1.5 hrs and the signal was developed with
ECL reagent (Thermo Fisher Scientific) and then imaged
with a Bio-Rad Chemidoc System. Densitometry was
performed using ImageJ software (NIH, Bethesda, MD).

fluorescence

DU-145 cells were seeded onto multiwell
chamberslides (Millipore, Billerica, MA) and were left to
adhere overnight. For the drug-uptake studies, cells were
incubated with 5 µM of the unconjugated doxorubicin
or AEZS-108 for 20 or 60 minutes, respectively. The
nucleus marker Hoechst 33342 dye (Life Technologies)
was added 10 minutes before the end of the incubation.
Cells were then washed 3 times with PBS, were fixed
in 4% paraformaldehyde for 15 minutes, and mounted
in Vectashield mounting medium (Vector Laboratories,
Burlingame, CA). Fluorescence was detected by a Nikon
Eclipse Ti fluorescence microscope (Nikon Instruments,
Melville, NY).
For immunocytochemistry, cells were incubated
with 5 µM the unconjugated doxorubicin or AEZS-108,
respectively, for 60 minutes. Afterwards, cells were washed
with PBS 3 times and fixed in 4% paraformaldehyde for 7
minutes. Permeabilization was performed by a 10-minute
incubation in PBS containing 0.2 % Triton-X and then
cells were blocked with 2% goat serum in PBS for 30 min.
A specific antibody against the phosphorylated (at Ser139)
histone variant γ-H2AX (1:50 dilution, Cell Signalling
Technology, Danvers, MA) or the human LHRH receptor
(1:100 dilution, Abcam, Cambridge, MA) was diluted in
PBS and added to the cells for one hour. Anti-rabbit or
anti-goat secondary antibodies (Alexa Fluor 488; Jackson
Immunoresearch, West Grove, PA) were also applied for
1 h. Coverslips were mounted in Vectashield mounting
medium containing DAPI for nuclear staining (Vector
Laboratories). Images were acquired on a Nikon Eclipse
Ti fluorescence microscope.

Statistical analysis
Statistical analyses were performed using analysis
of variance (ANOVA) followed by Holm-Sidak post hoc
test calculated by Sigma Plot software (Systat Software
Inc, Chicago, IL). Results are expressed as the means ±
SEM. Differences with p<0.05, compared to the control,
were considered statistically significant.
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